What Changed
- Planned submission of a bill to LegCo by the end of 2026 to establish the Hong Kong Centre for Medical Products Regulation.
- Transition of the drug registration system toward 'primary evaluation' independent of overseas regulatory approvals.
- Expansion of Chinese medicine internationalisation strategies and local healthcare training infrastructure, including establishing a third medical school.
The Legislative Council (LegCo) Secretariat of the Hong Kong Special Administrative Region (Hong Kong SAR) released a Policy Pulse titled "Developing an international health and medical innovation hub: Reform of medical products and inheritance of Chinese medicine." The publication outlines measures to reform Hong Kong SAR's regulatory regime for drugs and medical devices, advance Chinese medicine (CM) development, and summarize related LegCo discussions and Member recommendations.
**Key Regulatory Initiatives**
To establish Hong Kong SAR as an international health and medical innovation hub, the government plans to submit a bill to LegCo by the end of 2026 to establish the Hong Kong Centre for Medical Products Regulation. This center aims to strengthen the regulatory infrastructure for medical products. Additionally, Hong Kong SAR is transitioning its new drug registration system toward a "primary evaluation" mechanism. This shift will allow new drug approvals without relying on prior registration approvals from overseas regulatory authorities, accelerating clinical applications. The government also intends to utilize the Greater Bay Area International Clinical Trial Institute in the Hetao Hong Kong Park to serve as a hub for converting medical innovations into clinical applications.
**Advancing Chinese Medicine and Healthcare Infrastructure**
In line with the Chinese Medicine Development Blueprint and the 2026 Policy Address, Hong Kong SAR aims to serve as a bridgehead for promoting Chinese medicine globally. LegCo Members recommended setting clear expansion targets for the Hong Kong Chinese Materia Medica Standards (HKCMMS) to enhance international standard-setting influence, alongside expanding government-subsidised CM services and funding for the Chinese Medicine Hospital of Hong Kong.
To support healthcare capacity, the government is expanding the local talent pool, including measures to recruit non-locally trained doctors. This aligns with target doctor-to-population ratios outlined in Hong Kong's First Five-Year Plan (2.43 doctors per 1,000 population). Furthermore, Hong Kong SAR is establishing its third medical school and setting up dedicated research funds to accelerate early-stage life and health technology development.
Who May Be Affected
Pharmaceutical companies, medical device manufacturers, biotechnology firms, healthcare professionals, clinical trial institutions, and patients in Hong Kong SAR and the Greater Bay Area.
Cross-Border Context
Hong Kong SAR serves as a bridgehead connecting international life sciences capital and research with Mainland China, particularly within the Guangdong-Hong Kong-Macao Greater Bay Area.
What to check next
- Introduction and gazetting of the bill to establish the Hong Kong Centre for Medical Products Regulation by the end of 2026.
- Regulatory updates on the full implementation timeline of the primary evaluation mechanism for new drug registrations.
This article provides general information and does not constitute legal advice. Consult the official text and obtain advice appropriate to your circumstances where needed.